Source: International Congress 2019 – Airway physiology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Pillai (Bangalore, India). Utility of FeNO in differentiating ACO and COPD. 357

Member's Comments

No comment yet.

Related content which might interest you: Diagnostic value of FeNO in COPD and asthma - COPD overlap syndrome Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Prediction of asthma exacerbations in children by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008 Characterization of airway inflammation in patients with asthma COPD overlap syndrome using FeNO levels Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation Year: 2008 Exhaled NO (FeNO) levels in patients with exacerbation of COPD and/or bronchiectasis Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Metabolomic analysis of exhaled breath condensate in patients with asthma and COPD Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 Exhaled NO (FENO) is superior to peak-flow monitoring in predicting exacerbation in asthmatics Source: Eur Respir J 2005; 26: Suppl. 49, 118s Year: 2005 Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap Source: Annual Congress 2013 –Is it really asthma? Year: 2013 Differences in plasma and sputum biomarkers between COPD and COPD–asthma overlap Source: Eur Respir J 2014; 43: 421-429 Year: 2013 The usefulness of the simultaneous measurement of IOS and FeNO in the management of asthma Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases Year: 2012 Role of biomarkers in the assessment and phenotyping asthma and COPD Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Decreased levels of bis-S-bimane in exhaled breath condensate of COPD Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015 The influence of asthma and COPD exacerbation on exhaled mitric oxide (FENO) Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004 Temporal stability of feno measurement in COPD Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Pulmonary biomarkers in asthma and COPD Source: Annual Congress 2007 - PG13 - Outcome measures of clinical trials for new drugs for respiratory disease Year: 2007 Assessment of diagnostic accuracy of lung function indices and FeNO for a positive methacholine challenge in suspected asthmatics Source: International Congress 2018 – Asthma management Year: 2018 Usefulness of fractional exhaled nitric oxide (FeNO) for early diagnosis of asthma in patients with nonspecific respiratory symptoms Source: Annual Congress 2009 - From cough to sound analysis of breathing Year: 2009 Diagnosing asthma and prognostic significance of eNO Source: Annual Congress 2005 - Are we ready for "inflammometry"? The role of eNO in asthma management Year: 2005 Usefulness of fraction of exhaled nitric oxide and asthma management questionnaires in predicting a future risk of asthma exacerbation Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019